Cardiovascular outcomes data from the CANVAS Program and EMPA-REG OUTCOME, together with forthcoming data from DECLARE, will help to inform any potential SGLT2 inhibition-mediated cardioprotective effects in updates to the ECHO-T2DM model. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.